IRADIMED CORPORATION

Report azionario NasdaqGM:IRMD

Capitalizzazione di mercato: US$1.1b

IRADIMED Gestione

Criteri Gestione verificati 4/4

IRADIMED Il CEO è Roger Susi, nominato in Jan2004, e ha un mandato di 22.25 anni. la retribuzione annua totale è $ 689.58K, composta da 48.9% di stipendio e 51.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 34.64% delle azioni della società, per un valore di $ 371.28M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 6.8 anni.

Informazioni chiave

Roger Susi

Amministratore delegato

US$689.6k

Compenso totale

Percentuale dello stipendio del CEO48.93%
Mandato del CEO22.3yrs
Proprietà del CEO34.6%
Durata media del management4.3yrs
Durata media del Consiglio di amministrazione6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating

Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.

IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating

Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.

IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing

Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.

IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple

Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.

IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support

Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.

IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook

Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.

IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced

Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.

IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks

Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.

IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks

IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.

IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum

Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.

IRMD: Index Addition and Strong Margins Will Support Measured Upside

Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.

Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?

Oct 09
Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?

IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up

Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up

IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues

Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues

Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns

Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
User avatar

Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins

Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17
Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Roger Susi rispetto agli utili di IRADIMED?
DataCompenso totaleStipendioUtili della società
Dec 31 2025n/an/a

US$22m

Sep 30 2025n/an/a

US$21m

Jun 30 2025n/an/a

US$21m

Mar 31 2025n/an/a

US$20m

Dec 31 2024US$690kUS$337k

US$19m

Sep 30 2024n/an/a

US$19m

Jun 30 2024n/an/a

US$19m

Mar 31 2024n/an/a

US$18m

Dec 31 2023US$643kUS$308k

US$17m

Sep 30 2023n/an/a

US$16m

Jun 30 2023n/an/a

US$15m

Mar 31 2023n/an/a

US$14m

Dec 31 2022US$586kUS$290k

US$13m

Sep 30 2022n/an/a

US$13m

Jun 30 2022n/an/a

US$12m

Mar 31 2022n/an/a

US$10m

Dec 31 2021US$615kUS$308k

US$9m

Sep 30 2021n/an/a

US$6m

Jun 30 2021n/an/a

US$5m

Mar 31 2021n/an/a

US$987k

Dec 31 2020US$435kUS$290k

US$1m

Sep 30 2020n/an/a

US$4m

Jun 30 2020n/an/a

US$5m

Mar 31 2020n/an/a

US$10m

Dec 31 2019US$488kUS$288k

US$10m

Compensazione vs Mercato: La retribuzione totale di Roger ($USD 689.58K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.70M ).

Compensazione vs guadagni: La retribuzione di Roger è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Roger Susi (72 yo)

22.3yrs
Mandato
US$689,580
Compensazione

Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Roger Susi
Founder22.3yrsUS$689.58k34.64%
$ 371.3m
John Glenn
CFO & Corporate Secretary3.8yrsUS$1.26m0.066%
$ 709.3k
Jeff Chiprin
Chief Commercial Officer1.4yrsUS$483.87kNessun dato
Randy Waddell
Vice President of Worldwide Sales & Marketing4.8yrsUS$597.28kNessun dato
Chris Williamson
Executive Vice President of Continuous Improvement & Information Technology3.8yrsNessun datoNessun dato
Matt Garner
Controller6.3yrsNessun datoNessun dato
Lynn Neuhardt
Vice President of Research & Developmentno dataUS$442.20kNessun dato
4.3yrs
Durata media
63yo
Età media

Gestione esperta: Il team dirigenziale di IRMD è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Roger Susi
Founder9.8yrsUS$689.58k34.64%
$ 371.3m
James Hawkins
Director6.8yrsUS$149.95k0.23%
$ 2.5m
Joseph Kiani
Directorless than a yearNessun datoNessun dato
Monty Allen
Independent Director12.3yrsUS$169.95k0.16%
$ 1.8m
Hilda Scharen-Guivel
Independent Director3.5yrsUS$162.45k0.067%
$ 720.9k
6.8yrs
Durata media
69yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IRMD sono considerati esperti (durata media dell'incarico 6.8 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/04/30 16:37
Prezzo dell'azione a fine giornata2026/04/29 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

IRADIMED CORPORATION è coperta da 4 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Lawrence SolowCJS Securities, Inc.
Ilya ZubkovFreedom Broker
Frank TakkinenLake Street Capital Markets, LLC